These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17417738)

  • 1. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
    Müller T; Woitalla D; Russ H; Hock K; Haeger DA
    J Neural Transm (Vienna); 2007; 114(8):1023-6. PubMed ID: 17417738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
    Giladi N; Ghys L; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1345-51. PubMed ID: 25444083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management approaches to dyskinesia vary from country to country.
    Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
    Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
    Walker RW; Howells AR; Gray WK
    Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classifying risk factors for dyskinesia in Parkinson's disease.
    Sharma JC; Bachmann CG; Linazasoro G
    Parkinsonism Relat Disord; 2010 Sep; 16(8):490-7. PubMed ID: 20598622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful orchestration of antiparkinsonian pharmacotherapy.
    Scheife RT
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):180S-6S. PubMed ID: 10555946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF; Bonnet AM; Vidailhet M; Agid Y
    Neurology; 1996 Jun; 46(6):1548-51. PubMed ID: 8649546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation.
    Simoni S; Paoletti FP; Eusebi P; Cappelletti G; Filidei M; Brahimi E; Nigro P; Santangelo V; Parnetti L; Calabresi P; Tambasco N
    J Parkinsons Dis; 2020; 10(3):927-934. PubMed ID: 32280105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.